Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company developing engineered immunotherapies for cancer and other serious diseases. Its core platform is the D-Domain synthetic binding scaffold, which the company uses to build CAR-T and related cell therapy candidates designed to be more controllable, potentially safer, and easier to manufacture than conventional scFv-based CAR-Ts. The company’s lead asset is anitocabtagene autoleucel (anito-cel), a BCMA-targeting ddCAR being studied in multiple myeloma through pivotal and late-stage trials. Arcellx also is advancing ARC-SparX, a dosable and controllable universal CAR-T platform, and is exploring applications beyond oncology, including autoimmune disease. The business is still pre-commercial and relies on collaboration revenue, external funding, and partnerships such as its co-development/co-commercialization arrangement with Kite Pharma.

−1 105,6 %

−1 027,3 %

−79,4 %

4.44

— Arcellx, Inc.
	%
Lead CAR-T therapy candidates	55% Clinical-stage cell therapy assets centered on anito-cel and related CAR-T programs for oncology.
Universal CAR-T platform	20% ARC-SparX and related technologies that aim to make CAR-T dosing more controllable and adaptable.
Discovery and preclinical pipeline	15% Earlier-stage programs extending the D-Domain platform into new oncology and non-oncology indications.
Collaboration and license revenue	10% Revenue recognized from the Kite collaboration for partnered research and development work.

Arcellx does not yet sell approved products to end customers; its current economic counterparties are collaboration...

Strategic collaboration partnerprimary
Kite Pharma collaborates on anito-cel development and future commercialization, providing funding, development support, and commercial reach.
Clinical trial sites and investigatorsprimary
Academic and community centers enroll patients in pivotal and Phase 2 studies needed to generate regulatory data.
Hematology-oncology treatment centersprimary
Hospitals and cellular therapy programs would administer approved CAR-T products to multiple myeloma and other cancer patients.
Patients with refractory hematologic malignanciesprimary
Patients with multiple myeloma and other hard-to-treat cancers are the intended end users of the company’s lead therapies.
Potential autoimmune-disease patientsemerging
Future non-oncology programs could address autoimmune diseases if the platform proves clinically and commercially viable.

Arcellx is headquartered in Redwood City, California, with additional research and office operations in Rockville,...

•Headquartered in Redwood City, California
•Research, lab, and office facilities in Rockville, Maryland
•U.S. is the main operating and development base
•Kite handles ex-U.S. commercialization for anito-cel if approved
•Global IP and regulatory filings matter for future market access

Arcellx’s strategy is to convert its D-Domain platform into differentiated cell therapies that can overcome key...

Complete late-stage development of anito-celshort-term

Regulatory success in multiple myeloma is the most direct path to first commercial value and validation of the platform.

Leverage the Kite collaboration for commercializationshort-term

Partnering reduces the need to build a large commercial infrastructure before approval and improves launch readiness.

Advance ARC-SparX and next-generation platform programsmedium-term

A broader platform could create multiple shots on goal and reduce dependence on a single lead asset.

Protect intellectual property and freedom to operatemedium-term

Cell therapy is highly patent-intensive, and durable IP is essential to commercialization and partnering leverage.

Arcellx faces the classic risks of a clinical-stage biotech company: clinical failure, regulatory delay, and the...

critical

Clinical development risk for anito-cel and ARC-SparX

The company’s value depends on positive pivotal and late-stage data; failure would materially reduce commercialization prospects.

Scope: Lead program and platform pipeline
Materiality: high

critical

Regulatory approval risk

The company cannot generate product sales until regulators approve its candidates, and review delays would push out revenue.

Scope: FDA and other health authorities
Materiality: high

high

Dependence on Kite collaboration

A large share of development and future commercialization for anito-cel depends on a single strategic partner.

Scope: Co-development and co-commercialization
Materiality: high

high

Intellectual property litigation and freedom-to-operate risk

Competing patents or infringement claims could delay programs or force licensing on unfavorable terms.

Scope: D-Domain platform and product candidates
Materiality: high

high

Financing and dilution risk

The company expects continued operating losses and may need external capital before product revenue exists.

Scope: Pre-commercial funding needs
Materiality: high

Kite collaboration revenue recognition

Affects revenue timing, contract liabilities, and comparability across periods

Research and development expense allocation

Affects operating expense trend analysis and pipeline valuation

Stock-based compensation

Affects reported losses and dilution analysis

Operating lease accounting

Affects balance sheet leverage and operating expense presentation

Arcellx, Inc.

Clinical development risk for anito-cel and ARC-SparX

Regulatory approval risk

Dependence on Kite collaboration

Intellectual property litigation and freedom-to-operate risk

Financing and dilution risk

Arcus Biosciences, Inc.

Atara Biotherapeutics, Inc.

BioAtla, Inc.

Aptevo Therapeutics Inc.

Autolus Therapeutics plc

Arcturus Therapeutics Holdings Inc.